U.S. markets open in 5 hours 52 minutes

Constellation Pharmaceuticals, Inc. (CNST)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.11-0.51 (-1.43%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close35.62
Open36.15
Bid0.00 x 1300
Ask0.00 x 800
Day's Range34.56 - 36.69
52 Week Range17.00 - 50.90
Volume407,983
Avg. Volume696,017
Market Cap1.67B
Beta (5Y Monthly)2.79
PE Ratio (TTM)N/A
EPS (TTM)-2.71
Earnings DateMar 08, 2021 - Mar 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.22
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation
    Benzinga

    Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation

    After strong performance in 2020, biopharma stocks are expected to continue their winning run in the new year.Among the companies in the space, analysts at BMO Capital Markets are particularly bullish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN and Constellation Pharmaceuticals Inc (NASDAQ: CNST).The Regeneron, Constellation Analysts: Analyst Matthew Luchini upgraded Regeneron from Neutral to Outperform and maintained the price target at $630.Analyst Do Kim upgraded Constellation shares from Market Perform to Outperform and increased the price target from $27 to $50.The Regeneron Thesis: The potential exists for continued strong performance from Regeneron's retinal disorder treatment Eylea, the dermatitis and asthma drug Dupixent and the advanced cutaneous squamous cell carcinoma treatment Libtayo, Luchini said in the upgrade note.Additional opportunities are available in the form of ongoing Dupixent label expansion efforts and a combined-focused oncology pipeline, the analyst said. The COVID-19 antibody treatment REGN-CoV2, though not central to BMO's thesis, provides near-term profit, Luchini said.Regeneron, the analyst said, is well-positioned heading into 2021."Given our positive view on Regeneron's fundamentals and optionality provided by the pipeline we believe current levels provide an attractive entry point." Related Link: The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More The Constellation Thesis: Following Constellation's decision to start a Phase 2 study evaluating CPI-0209 in in EZH2-mutated diffuse large B-cell lymphoma, prostate cancer and solid tumors, BMO has included revenue estimates for the candidate in its model, Kim said.The analyst estimates worldwide peak sales of $2.3 billion, with a blended 24% probability of success.Clinical benefit from EZH2 inhibition has been validated by Epizyme Inc's (NASDAQ: EPZM) Tazverik, which is approved in EZH2-mutated follicular lymphoma, he said.CPI-0209's more potent inhibition has a better chance of showing improved benefit in the aggressive NHL subtype, Kim said. Interim CPI-0209 Phase 1 data is expected in mid-2021, with a Phase 2 start shortly after, the analyst said. The upwardly revised price target reflects the addition of probability-adjusted CPI-0209 revenues, according to BMO. The Regeneron, Constellation Price Action: At last check, Regeneron shares were advancing 0.51% to $540.51 and Constellation shares were down 1.24% at $224.09. Related Link: The Gilead, Galapagos Pipeline Opportunities That Are Turning Morgan Stanley Bullish Latest Ratings for REGN DateFirmActionFromTo Jan 2021BMO CapitalUpgradesMarket PerformOutperform Jan 2021Morgan StanleyMaintainsEqual-Weight Jan 2021CitigroupMaintainsBuy View More Analyst Ratings for REGN View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * Moderna: mRNA Coronavirus Vaccine Works Against Multiple Strains * Merck Drops COVID-19 Vaccine Studies After Phase 1 Data Churn Out Inferior Efficacy Results(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer
    GlobeNewswire

    Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer

    CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building and leading the Company’s commercial organization and pre-launch preparations in support of CPI-0610, which has the potential to be a disease-modifying therapy for patients living with myelofibrosis. “Brendan is joining Constellation at a pivotal time, and I look forward to working with him to advance the treatment paradigm for patients with myelofibrosis,” said Jigar Raythatha, President and Chief Executive Officer of Constellation Pharmaceuticals. “With more than 25 years of experience in hematology and oncology commercialization, Brendan’s expertise will be invaluable as we prepare for the potential launch of our first product, CPI-0610—the first potential new myelofibrosis therapy beyond JAK inhibitors.”“I am excited to join Constellation and look forward to leading preparations for the Company’s first commercial product launch,” said Brendan Delaney, Chief Commercial Officer of Constellation Pharmaceuticals. “It’s gratifying to work toward advancing the standard of care for patients with myelofibrosis. CPI-0610 is a highly promising Phase 3 product candidate with the potential to address unmet medical needs that have been identified by both patients and physicians.”Mr. Delaney has a track record of global commercial success that spans more than two decades in the biopharmaceutical industry. Prior to joining Constellation, Mr. Delaney served as Chief Commercial Officer at Immunomedics, where he built and led the marketing, sales, market access, and commercial operations teams in preparation for that Company’s first commercial product launch. Previously, he served in several senior positions of increasing responsibility at Celgene, including most recently as Vice President, U.S. Commercial Hematology Oncology. Earlier in his career, Brendan held various sales, marketing and product management roles at Novartis Oncology and Genentech, where he directed successful product launches for several blockbuster brands. He earned an MBA from the Stern School of Business at New York University and a B.A. in biology from Rutgers University.About Constellation Pharmaceuticals Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is advancing development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative, small-molecule product candidates.Forward-Looking Statements  This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the Company’s regulatory and commercial plans and prospects of the Company’s product candidate, CPI-0610.  Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to: obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials; obtain, maintain, or protect intellectual property rights related to its product candidates; manage expenses; raise the substantial additional capital needed to achieve its business objectives; the COVID-19 pandemic; and general economic and market conditions. For a discussion of other risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission.Contacts Kia Khaleghpour, Ph.D.  Vice President, Investor Relations and Communications  Constellation Pharmaceuticals  +1 617-844-6859  kia.khaleghpour@constellationpharma.com     Lauren Arnold  Media Relations  MacDougall Biomedical Communications  +1 781-235-3060  larnold@macbiocom.com

  • Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
    GlobeNewswire

    Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P. Morgan Healthcare Conference at 10:50 AM EST on Thursday, January 14, 2021. A live audio webcast of the presentation and archive for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replay will be available for 30 days following the live presentation.About Constellation Pharmaceuticals Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.ContactsKia Khaleghpour, Ph.D. Vice President, Investor Relations and Communications Constellation Pharmaceuticals +1 617-844-6859 kia.khaleghpour@constellationpharma.comLauren Arnold Media Relations MacDougall Biomedical Communications +1 781-235-3060 larnold@macbiocom.com